Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Memory enhancers and treatments for age-related memory decline - myst or reality?
As their owners dogs and cats have a longer life span than ever before. But at the same time the cognitive decline in animals is seen much more than in the generations before. A varitey of nutrients and `medications`, often with nonprescription compounds, is offered. Do they really show any benefit? A very important study from Canada.

We review the experimental evaluations of several widely marketed nonprescription compounds claimed to be memory enhancers and treatments for age-related memory decline. We generally limit our review to double-blind placebo-controlled studies.

The compounds examined are phosphatidylserine (PS), phosphatidylcholine (PC), citicoline, piracetam, vinpocetine, acetyl-L-carnitine (ALC), and antioxidants (particularly vitamin E). RESULTS: In animals, PS has been shown to attenuate many neuronal effects of aging, and to restore normal memory on a variety of tasks.

Preliminary findings with humans, though, are limited.

For older adults with probable Alzheimer`s disease, a single study failed to demonstrate positive effects of PS on memory performance.

For older adults with moderate cognitive impairment, PS has produced consistently modest increases in recall of word lists.

Positive effects have not been as consistently reported for other memory tests.

There is one report of consistent benefits across a number of memory tests for a subset of normal adults who performed more poorly than their peers at baseline.

The choline compounds PC and citicoline are thought to promote synthesis and transmission of neurotransmitters important to memory.

PC has not proven effective for improving memory in patients with probable Alzheimer`s disease.

The issue remains open for older adults without serious degenerative neural disease.

Research on citicoline is practically nonexistent, but one study reported a robust improvement in story recall for a small sample of normally aging older adults who scored lower than their peers in baseline testing.

Animal studies suggest that piracetam may improve neuronal efficiency, facilitate activity in neurotransmitter systems, and combat the age-related decrease in receptors on the neuronal membrane.

However, for patients with probable Alzheimer`s disease, as well as for adults with age-associated memory impairment, there is no clear-cut support for a mnemonic benefit of piracetam.

Vinpocetine increases blood circulation and metabolism in the brain.

Animal studies have shown that vinpocetine can reduce the loss of neurons due to decreased blood flow.

In three studies of older adults with memory problems associated with poor brain circulation or dementia-related disease, vinpocetine produced significantly more improvement than a placebo in performance on global cognitive tests reflecting attention, concentration, and memory.

Effects on episodic memory per se have been tested minimally, if at all. ALC participates in cellular energy production, a process especially important in neurons, and in removal of toxic accumulation of fatty acids.

Animal studies show that ALC reverses the age-related decline in the number of neuron membrane receptors.

Studies of patients with probable Alzheimer`s disease have reported nominal advantages over a range of memory tests for ALC-treated patients relative to placebo groups.

Significant differences have been reported rarely, however. Whether ALC would have mnemonic benefits for aging adults without brain disease is untested as far as we know.

Antioxidants help neutralize tissue-damaging free radicals, which become more prevalent as organisms age. It is hypothesized that increasing antioxidant levels in the organism might retard or reverse the damaging effects of free radicals on neurons.

Thus far, however, studies have found that vitamin E does not significantly slow down memory decline for Alzheimer`s patients and does not produce significant memory benefits among early Parkinson`s patients.

Neither did a combination of vitamins E and C significantly improve college students` performance on several cognitive tasks.

CONCLUSIONS: In sum, for most of the `brain-specific` nutrients we review, some mildly suggestive effects have been found in preliminary controlled studies using standard psychometric memory assessments or more general tests designed to reveal cognitive impairment. We suggest that future evaluations of the possible memory benefits of these supplements might fruitfully focus on memory processes rather than on memory tests per se.

Source: McDaniel MA, Maier SF, Einstein GO. (2003): `Brain-specific` nutrients: a memory cure? In: Nutrition. 2003 Nov-Dec;19(11-12):957-75.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Long-term outcome of dogs with primary immune-mediated thrombocytopeniamembers
Primary immune‐mediated thrombocytopenia (IMTP) is a life-threatening condition which is occasionally seen in dogs. Also many of them respond to intensive therapy, the incidence of relapse may be underestimated. The objectives of this new study were to determine the incidence of relapse after discharge from the hospital in dogs with a diagnosis of presumed primary immune‐mediated thrombocytopenia, risk factors associated with relapse and whether or not indefinite use of immunosuppressive medication influences risk of relapse.

  • Insulin treatment and IGF-I in cats with diabetes mellitusmembers
  • Color doppler ultrasound in neoplastic and non-neoplastic canine testicles members
  • Computed tomographic arthrography of the canine shoulder joint members
  • Prognostic scoring system for dogs managed with hemodialysismembers
  • Sonography vs percutaneous palpation to identify targeted thoracolumbar intervertebral disc spacesmembers
  • Distribution of alveolar-interstitial syndrome in dogs and cats with respiratory distress members
  • Disorders of sex development in catsmembers
  • Core ocular surface microbiome in dogsmembers
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics members
  • MRI imaging of masticatory muscles in basset houndsmembers
  • Mucosal microbiota, gastrointestinal inflammation and small cell intestinal lymphoma in cats members
  • Efficacy of pentamidine analogue 6 in dogs with chronic atrial fibrillationmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved